Image of Salmaan A. Keshavjee

Salmaan A. Keshavjee, M.D., Ph.D.

Professor of Global Health and Social Medicine Medical Anthropology, Harvard Medical School
Associate Professor of Medicine, Brigham and Women's Hospital
Faculty Dean of Adams House, Faculty of Arts & Sciences
Interim Director of the Center for Middle Eastern Studies, Faculty of Arts & Sciences
Affiliate of the Department of Anthropology, Faculty of Arts & Sciences

Salmaan Keshavjee, MD, PhD, ScM, is the Director of Harvard Medical School’s Center for Global Health Delivery and Professor of Global Health and Social Medicine in the Department of Global Health and Social Medicine (DGHSM) at Harvard Medical School. He is also Associate Professor of Medicine in the Division of Global Health Equity at Brigham and Women’s Hospital.

Dr. Keshavjee has been leading the Harvard Medical School Center for Global Health Delivery since 2014. Under his direction, the Center addresses some of the most pressing global health challenges by focusing on research, medical education and training that promises to improve healthcare delivery systems and patient outcomes for diseases prevalent in the United Arab Emirates, Middle East, North Africa and neighboring regions. The Center also provides opportunities for faculty and students to pursue research related to the delivery of existing or new interventions that can cure or prevent disease, specifically in the following priority areas: diabetes and obesity, infectious disease, mental health, and surgery.

With advanced training in both medicine and anthropology, Dr. Keshavjee is a leading expert in drug-resistant tuberculosis treatment and the anthropology of health policy. He is the author of Blind Spot: How neoliberalism infiltrated global health­.  He has worked extensively with the Boston-based non-profit Partners In Health (PIH) on the treatment of drug-resistant tuberculosis.  Over the last 16 years, Dr. Keshavjee has conducted clinical and implementation research in Russia (2000-present).  He was also the Deputy-Director for the Partners In Health’s Lesotho Initiative (2006-2008), launching one of the first community-based treatment programs for multi-drug resistant tuberculosis/HIV co-infection in sub-Saharan Africa. His research has resulted in a number of clinical and policy manuscripts on TB and MDR-TB, which have had significant clinical and policy impact.   

Dr. Keshavjee has been very involved in global policy discussions around the treatment of drug-resistant tuberculosis.  In 2005, he became a member of the World Health Organization/Stop TB Partnership’s Green Light Committee for MDR-TB Treatment.  From 2007 to 2010, he was the committee’s chair.  He has spent considerable time working on alternate mechanisms for drug procurement, technical assistance delivery, and program implementation.  In addition to acting as a consultant to a number of projects globally, Dr. Keshavjee was the co-author of a U.S. Institute of Medicine white paper on overcoming barriers to expanding treatment for MDR-TB. 
Dr. Keshavjee is leading an initiative at Harvard Medical School on how to achieve zero deaths from tuberculosis, and has been working with global partners to build the Zero TB Cities Initiative.   
 

Address: 
641 Huntington Avenue
Boston, MA 02115

Engaging the private sector to increase tuberculosis case detection: an impact evaluation study.
Authors: Authors: Khan AJ, Khowaja S, Khan FS, Qazi F, Lotia I, Habib A, Mohammed S, Khan U, Amanullah F, Hussain H, Becerra MC, Creswell J, Keshavjee S.
Lancet Infect Dis
View full abstract on Pubmed
Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
Authors: Authors: Floyd K, Hutubessy R, Kliiman K, Centis R, Khurieva N, Jakobowiak W, Danilovits M, Peremitin G, Keshavjee S, Migliori GB.
Eur Respir J
View full abstract on Pubmed
Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome.
Authors: Authors: Keshavjee S, Gelmanova IY, Shin SS, Mishustin SP, Andreev YG, Atwood S, Furin JJ, Miller A.
Int J Tuberc Lung Dis
View full abstract on Pubmed
Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence.
Authors: Authors: Satti H, McLaughlin MM, Omotayo DB, Keshavjee S, Becerra MC, Mukherjee JS, Seung KJ.
PLoS One
View full abstract on Pubmed
Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience.
Authors: Authors: Furin J, Gegia M, Mitnick C, Rich M, Shin S, Becerra M, Drobac P, Farmer P, Hurtado R, Joseph JK, Keshavjee S, Kalandadze I.
Bull World Health Organ
View full abstract on Pubmed
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.
Authors: Authors: Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ.
PLoS Med
View full abstract on Pubmed
Time for zero deaths from tuberculosis.
Authors: Authors: Keshavjee S, Harrington M, Gonsalves G, Chesire L, Farmer PE.
Lancet
View full abstract on Pubmed
Programmatic management of multidrug-resistant tuberculosis: models from three countries.
Authors: Authors: Furin J, Bayona J, Becerra M, Farmer P, Golubkov A, Hurtado R, Joseph JK, Keshavjee S, Ponomarenko O, Rich M, Shin S.
Int J Tuberc Lung Dis
View full abstract on Pubmed
In reply to '"Universal" access for MDR-TB limited without the involvement of the private sector' [Correspondence].
Authors: Authors: Keshavjee S, Farmer P.
Int J Tuberc Lung Dis
View full abstract on Pubmed
Rational use of moxifloxacin for tuberculosis treatment.
Authors: Authors: Cox H, Ford N, Keshavjee S, McDermid C, von Schoen-Angerer T, Mitnick C, Goemaere E.
Lancet Infect Dis
View full abstract on Pubmed